Proteins and Peptides

03 Feb 2022 Synthekine Doses First Patient in Phase 1 Clinical Trial of IL-2 Partial Agonist, STK-012, for Treatment of Solid Tumors
31 Jan 2022 FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)
28 Jan 2022 Simcha Therapeutics Raises $40 Million Series B Financing and Initiates Phase 1/2 Study to Evaluate Novel Interleukin-18 Variant in Cancer
25 Jan 2022 Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics’ Novel Bifunctional Fusion Protein
25 Jan 2022 Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency
22 Jan 2022 Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors
18 Jan 2022 Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 2b Clinical Trial Evaluating XW003, its Lead GLP-1 Drug Candidate, for the Treatment of Obesity
14 Jan 2022 Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa
13 Jan 2022 Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency
13 Jan 2022 Zhittya Genesis Medicine Starts Parkinson’s Disease Clinical Trial
10 Jan 2022 Peptilogics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Trial of PLG0206 in Periprosthetic Joint Infection
10 Jan 2022 Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
07 Jan 2022 Sapience Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ST101
05 Jan 2022 Allena Pharmaceuticals Provides Clinical and Corporate Update
04 Jan 2022 Radiomedix and Orano Med Announce the Initiation of the Phase II Multi-Center Clinical Trial of Alphamedix™ for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers
29 Dec 2021 Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye Disease
29 Dec 2021 Hansa Biopharma enrolls first patient in U.S. randomized, controlled pivotal trial of imlifidase in highly sensitized kidney transplant patients
21 Dec 2021 Lannett announces submission of investigational new drug (IND) application for biosimilar insulin glargine
16 Dec 2021 Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Atopic Dermatitis
15 Dec 2021 Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
15 Dec 2021 ACELYRIN, INC., Affibody AB, and Inmagene Biopharmaceuticals Announce Positive Interim Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis
15 Dec 2021 First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001
12 Dec 2021 Jazz Pharmaceuticals Presents Positive Interim Phase 2/3 Results of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at ASH 2021 Annual Meeting
08 Dec 2021 SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
07 Dec 2021 Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up